RegeneRx Biopharmaceuticals, Inc. (NYSE Amex:RGN) announced today that it has been awarded a $3 million grant from the National Institutes of Health's National Heart, Lung and Blood Institute to support and accelerate the clinical development of its novel product candidate RGN-352, an injectable formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4, for patients who have suffered an acute myocardial infarction, or AMI, commonly known as a heart attack. The award is being issued under the American Reinvestment and Recovery Act of 2009. The Company is planning to initiate a Phase 2 clinical trial with RGN-352 later this year.
This highly competitive grant award will allow the Company to conduct a number of key scientific activities in parallel that should facilitate the commercial development of RGN-352.
CKM syndrome leads to elevated cardiovascular disease risk earlier in life